Dr Kumud Dhital, CEO of COVIRIX Medical says:

"A global study of Upper Respiratory Tract Infections (URTIs) in 204 countries between 1990 to 2019 found a significant burden of URTIs reaching 17.2 billion cases in 2019 alone. Given that respiratory viruses account for over 80% of URTIs, there is significant unmet medical need for a well-tolerated antiviral that can treat a wide range of respiratory diseases and can also be applied for preventive purposes. COVIRIX Medical's broad-spectrum repurposed drug targets and inhibits a host enzyme used by a wide range of respiratory viruses, including those with pandemic potential such as Avian Influenza and SARS-CoV-2. Through a patented repurposed formulation, it is administered via oral inhalation and directed immediately to the site of action in the lungs. COVIRIX Medical has already completed pre-clinical studies on SARS CoV-2 and its multiple variants with positive results. Subject to appropriate clinical trial results, it is anticipated that the drug may be used for prevention and treatment of other viral respiratory tract diseases."